There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ligand Pharma (LGND – Research Report) and Virpax Pharmaceuticals (VRPX – Research Report) with bullish sentiments.
Virpax Pharmaceuticals (VRPX)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Monday at $0.77.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Virpax Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LGND:
